SurVaxM Brain Cancer Vaccine

Thursday, September 27, 2012

A new clinical research study at Roswell Park, developed by Robert Fenstermaker, MD, and Michael Ciesielski, PhD, will test a first-of-its-kind cancer “vaccine” that may prove effective against many forms of solid-tumor cancers.

SurVaxM Additional Reading

Since this video was produced in September 2012, Drs. Fenstermaker and Ciesielski have made progress in studying the safety and effectiveness of SurVaxM. We encourage you to read the following updates about this promising brain cancer vaccine.

Immunotherapy Developed at Roswell Park Being Tested as Treatment for Multiple Myeloma
May 31, 2016

Promising Vaccine Therapy for Glioblastoma Brain Cancers Moves on to Larger, Multisite Study
September 9, 2015

Investigational Brain Cancer Vaccine Produces Strong Immunological Response
April 21, 2015